Project description
Cross-sectoral excellence hub advancing gene therapies
Gene therapy – changing or replacing faulty genes to prevent, treat or cure diseases – has shown tremendous promise in many areas but exploiting its full potential has faced challenges. The EU-funded GeneH project aims to create an excellence hub in gene therapy focused on life-threatening or chronically debilitating diseases that are considered incurable. The project’s core academic partners in Portugal and Slovenia have successful partnerships with industry, hospitals, policymakers, ecosystem/innovation supporters and patient associations. Through a cross-sectoral, multidimensional approach, the team will tackle challenges in research and development, translation, investment, regulatory and ethical issues while also providing educational and training programmes and engaging with society. Ultimately, GeneH plans to pave the way to clinical trials of innovative gene therapies.
Objective
GeneH proposes to create an excellence hub in gene therapy through strategic partnerships within and beyond Widening countries. Despite gene therapy's recognized priority in genomic medicine and its potential for high-curative economic impact, challenges persist in its development process, from conceptualization to commercialization. GeneH intends to address these challenges by serving as a catalyst for overcoming barriers and expediting research translation.
To achieve this, GeneH will establish a robust and sustainable hub that builds upon already established ecosystems in the field and recent H2020 WIDENING projects to implement centers of excellence in gene therapy (GeneT in PT and CTGCT in SL). The academic partners at its core, namely, the University of Coimbra (UC) in Portugal and the National Institute of Chemistry (KI/NIC) in Slovenia , have reached substantial achievements by partnering with industry (Bluepharma, Biocant Park, Biosistemika, Jafral), hospitals (CHUC EPE), policy makers (CCDRC, RRA LUR), ecosystem/innovation supporters (SIH EEIG, IPN), and patient associations (APAHE, ZOPS). Partners in the two ecosystems share a common goal: treating life-threatening or chronically debilitating diseases considered incurable. By harnessing the combined expertise and resources of its partners, GeneH aims to drive cross-sectoral collaboration through its 4-helix network, in a multidimensional approach that will gather further investment, address ethical and regulatory aspects, implement de-risking approaches, educational and training programes, joint R&I programs, and prepare the path for clinical trials of new gene therapy products, while actively engaging society.
By positioning itself as a leading hub in gene therapy, in line with regional, national, and European strategies, GeneH seeks to contribute to European competitive leadership globally, advancing healthcare, fostering economic growth, and making a positive societal impact.
Fields of science (EuroSciVoc)
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
CORDIS classifies projects with EuroSciVoc, a multilingual taxonomy of fields of science, through a semi-automatic process based on NLP techniques.
You need to log in or register to use this function
Keywords
Programme(s)
Funding Scheme
HORIZON-CSA - HORIZON Coordination and Support ActionsCoordinator
3004-531 Coimbra
Portugal